 Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the company continues to report growth and commercial prowess. I believe ZILRETTAs extended release properties makes it a go-to during the pandemic. 